Inhibition of osteoclastogenesis by Lf may have therapeutic potential for preventing bone loss associated with infectious diseases, periodontitis, and other inflammation-related diseases such as RA besides postmenopausal osteoporosis (41, 42). This evidence concerns the gene LTF and postmenopausal osteoporosis.